Abstract

Option Care Health Inc is scheduled to report first-quarter 2026 results on April 30, 2026 Pre-Market, with consensus pointing to year-over-year growth in revenue and adjusted EPS and the market watching for margin signals versus the December-quarter baseline.

Market Forecast

Market expectations for the current quarter anticipate revenue of 1.40 billion US dollars, reflecting an 11.33% year-over-year increase, EBIT of 79.63 million US dollars, up 4.43% year over year, and adjusted EPS of 0.37, up 22.92% year over year. There is no broadly disseminated consensus for the current-quarter gross profit margin or net margin, so the focus rests on revenue growth quality and the degree to which fixed-cost absorption and operating leverage translate into the forecast EPS step-up.

The company’s core payer mix remains anchored in the commercial channel, a structure that historically supports pricing integrity and scale benefits; consensus implies double-digit topline expansion this quarter while mix stability tends to be supportive for unit economics. Within that mix, the commercial book appears positioned to carry the strongest near-term contribution: it produced approximately 1.27 billion US dollars of revenue in the prior quarter, and the current-quarter topline outlook of 11.33% year-over-year growth suggests ongoing momentum even as seasonality moderates from the December period.

Last Quarter Review

In the December-quarter (fourth quarter of 2025), Option Care Health Inc delivered revenue of 1.46 billion US dollars, up 8.77% year over year, with a gross profit margin of 19.30%, GAAP net income attributable to shareholders of 58.50 million US dollars for a 3.99% net margin, and adjusted EPS of 0.46, up 31.43% year over year. Operating leverage was evident as EBIT increased 28.92% year over year to 112.21 million US dollars, while revenue marginally exceeded consensus and adjusted EPS was in line.

By payer channel, the business remained weighted to the commercial book, which accounted for roughly 86.78% of fourth-quarter revenue, equivalent to about 1.27 billion US dollars; the government channel contributed approximately 176.68 million US dollars and the patient-pay component approximately 16.99 million US dollars, with the overall company growing 8.77% year over year.

Current Quarter Outlook

Main business trajectory and margin checkpoints

The current quarter hinges on whether revenue strength can be matched by margin discipline relative to the fourth-quarter baseline. Consensus implies a top-line of 1.40 billion US dollars and adjusted EPS of 0.37, up 22.92% year over year, despite EBIT growth tracking more modestly at 4.43%; that spread highlights how investors will parse the interplay between gross margin, operating expense phasing, and below-the-line items. Against the December-quarter gross margin of 19.30% and net margin of 3.99%, stabilization or incremental improvement would validate efficiency gains and price/mix resilience; any slippage could pull the EPS translation below the implied run rate.

Within the main commercial channel—historically representing roughly 86.78% of mix—management’s execution on negotiated rates, service utilization, and case acuity should be the primary lever for profitability this quarter. The December result offered a useful benchmark with evidence of cost discipline and operating leverage in EBIT, and the coming print will test whether those efficiencies can be sustained in a seasonally lighter quarter. In parallel, the government channel balance will matter for mix: increased weighting here can dampen gross margin optics even as it supports absolute revenue, so investors will look for commentary that the channel composition is consistent with maintaining the December-quarter margin profile.

From a cash generation and quality-of-earnings perspective, working-capital cadence frequently drives quarterly variability; the market will listen for signals on receivable days and collections to corroborate earnings power. With consensus expecting EPS growth outpacing EBIT growth, lower non-operating drag and disciplined share-based or financing-related items can provide a cushion, but the core story must still track to operating metrics. Any deviation in gross margin relative to the 19.30% baseline is likely to receive outsized attention in the pre-market reaction, particularly if it conflicts with the year-over-year EPS step anticipated by consensus.

Most promising business and growth vectors

The commercial payer channel remains the most consequential growth vector given its scale and revenue density, contributing approximately 1.27 billion US dollars in the fourth quarter and serving as the core foundation for meeting the 11.33% year-over-year top-line growth targeted for the current quarter. The earnings model implied by consensus suggests that growth in this channel should deliver sufficient volume and mix to offset seasonal normalizations from the December quarter, while still expanding adjusted EPS at a faster clip than revenue. Maintaining that dynamic requires stable pricing, controlled service costs, and tight clinical and field operations to preserve unit margins.

On the expense side, the pathway to translating commercial growth into EPS is clearest when direct labor, supplies, and logistics scale efficiently with case growth. The December quarter’s 28.92% year-over-year jump in EBIT demonstrated the operating leverage potential; the current quarter tests the sustainability of that operating algorithm with a likely softer seasonal contribution. Investors will be attuned to whether the same levers—deployment efficiency and cost containment—remain intact, thereby enabling adjusted EPS to track toward the consensus 0.37 target.

The government channel’s contribution at approximately 176.68 million US dollars last quarter will be monitored as a complement to commercial growth. While this channel typically carries lower margin dynamics than commercial, it can provide steady volume, which can still be accretive to operating leverage if fixed costs are well absorbed. The patient-pay component at about 16.99 million US dollars remains a small part of the mix and is unlikely to drive headline results, but its trend can provide incremental insight into demand patterns and pricing sensitivity.

Key factors likely to influence the stock this quarter

Execution versus consensus on revenue and adjusted EPS is the first and most visible catalyst. The current-quarter revenue estimate sits at 1.40 billion US dollars and adjusted EPS at 0.37; a revenue print near the high end of expectations paired with even modest margin improvement could justify positive pre-market price action. Conversely, any shortfall in gross margin relative to 19.30% would raise questions about price/mix or cost inflation, particularly given that EBIT year-over-year growth is expected to be 4.43%, leaving less room for error on expense control.

Margin commentary will be the next focal point. Investors will benchmark reported gross and net margins against the December-quarter’s 19.30% and 3.99% levels, respectively, as a quick litmus for cost trajectory and mix effects. Because adjusted EPS growth is forecast to outpace revenue growth, the market implicitly expects tax, interest, and other non-operating items to be non-impediments; any surprise here—positive or negative—could amplify moves in the shares.

Finally, full-year setup matters for sentiment. Management has communicated a full-year 2026 adjusted EPS framework of 1.82 to 1.92; how the first-quarter run rate aligns with that range, and whether commentary reiterates or refines the trajectory, will shape post-print updates to models. A first-quarter cadence that tracks toward the midpoint of the range can reinforce confidence in the year plan, while a miss would require evidence of back-half levers to sustain the outlook. Cash flow conversion, working-capital management, and visibility into the payer pipeline are likely to be used as supporting details to underpin guidance confidence.

Analyst Opinions

Recent sell-side commentary over the past several months has skewed decisively bullish, with a 100% positive ratio among tracked updates, reflecting confidence that Option Care Health Inc can deliver on double-digit revenue growth and translate improved operating execution into higher adjusted EPS. Jefferies reiterated a Buy rating and a 43 US dollar price target, framing the stock as well positioned heading into the first-quarter release given consistent revenue execution and a constructive EPS cadence. Stephens likewise maintained a Buy with a 40 US dollar target, emphasizing that the company’s December-quarter beat on revenue and alignment on adjusted EPS build a supportive base for the upcoming print.

These positive stances are anchored in an identifiable bridge from recent results to near-term consensus. The fourth quarter produced 1.46 billion US dollars of revenue (+8.77% year over year) and 0.46 adjusted EPS (+31.43% year over year), while EBIT grew 28.92% to 112.21 million US dollars—evidence of operating leverage. For the current quarter, consensus sees 1.40 billion US dollars of revenue (+11.33% year over year) and 0.37 adjusted EPS (+22.92% year over year). Analysts leaning bullish are effectively arguing that the company can sustain enough gross margin stability around the 19.30% December-quarter level and contain operating costs such that the gap between revenue and EPS growth is bridged by leverage and disciplined non-operating items.

Institutional previews also point to key proof points investors will watch to validate the positive stance. One is revenue quality: maintaining a payer mix consistent with commercial-centric economics helps support gross margin and reduces the risk that growth comes at the expense of profitability. Another is cost control: commentary about staffing, logistics, and supply expense discipline during the quarter can confirm that the operating model remains on track even in a seasonally lighter period. Finally, reaffirming or tightening the full-year 2026 adjusted EPS range of 1.82 to 1.92 can serve as a confidence signal, particularly if first-quarter margins land at or above the December-quarter baseline.

The bullish camp’s implied risk calculus acknowledges that EBIT growth is forecast to trail revenue growth in the quarter (4.43% vs 11.33% year over year), which reduces the buffer for cost variability. However, supporters contend that the December-quarter’s margin performance provides enough foundation to absorb typical seasonal headwinds. They also note that adjusted EPS growth expected at 22.92% year over year suggests less drag below EBIT, allowing bottom-line growth to outpace operating income. In this frame, the bar for an upside reaction becomes a function of revenue landing near or above 1.40 billion US dollars while gross margin holds near 19% and expense discipline protects the EPS conversion.

Should results align with these contours, analysts argue the stock’s narrative can transition from a quarterly checkpoint toward year-long execution on the previously communicated EPS range. In that scenario, model revisions would likely focus on modestly higher revenue assumptions in the commercial channel, with only incremental tweaks to operating-cost assumptions if gross margin proves durable. If, however, margin shows unexpected compression relative to the 19.30% benchmark, bulls would expect management to articulate identifiable levers—such as mix normalization or expense offsets—to restore the EPS bridge over the remaining quarters.

In aggregate, the preponderance of institutional commentary remains on the positive side because the building blocks for consensus—double-digit revenue growth, leveraged EPS, and stable payer mix—are visible in the fourth-quarter baseline and in the current-quarter estimates. The upcoming report will provide the necessary validation on margins and operating costs; if delivered, the case for continued Buy ratings and targets in the low-40s remains intact in the eyes of the bullish majority.